Qureight has announced the appointment of Claus Torp Jensen to the role of Chairperson of the Board.
Qureight and Vicore Pharma publish results indicating that patients with earlier stage idiopathic pulmonary fibrosis (IPF) are more likely to have improvement in lung function in response to treatment with Vicore’s novel angiotensin II type 2 agonist, C21.
Cambridge-based data analytics company Qureight has entered into a multi-year collaboration with the biopharmaceutical company AstraZeneca.
The Qureight team is delighted to welcome Dr Pilar Rivera-Ortega on to our Scientific Advisory Board for Idiopathic Pulmonary Fibrosis (IPF).
Qureight is excited to be collaborating with the patientMpower team on a project to uncover new prognostic markers in interstitial lung disease (ILD).
Dr Muhunthan Thillai CEO said "We are really excited that Dr Fernandez has joined us to assist the company with our data strategy as we expand operations. Xose brings over 25 years’ experience...